123 related articles for article (PubMed ID: 20519807)
1. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
Aoki K; Miyazaki T; Nagakura J; Orime K; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):673-7. PubMed ID: 20519807
[TBL] [Abstract][Full Text] [Related]
2. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
[TBL] [Abstract][Full Text] [Related]
4. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
6. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
7. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
Aoki K; Kato H; Terauchi Y
Endocr J; 2007 Dec; 54(6):1009-14. PubMed ID: 18048991
[TBL] [Abstract][Full Text] [Related]
8. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
[TBL] [Abstract][Full Text] [Related]
9. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
10. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Narita T; Yokoyama H; Yamashita R; Sato T; Hosoba M; Morii T; Fujita H; Tsukiyama K; Yamada Y
Diabetes Obes Metab; 2012 Mar; 14(3):283-7. PubMed ID: 22051162
[TBL] [Abstract][Full Text] [Related]
12. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
13. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.
Aoki K; Kamiyama H; Masuda K; Kamiko K; Noguchi Y; Tajima K; Terauchi Y
Endocr J; 2014; 61(3):249-56. PubMed ID: 24389993
[TBL] [Abstract][Full Text] [Related]
14. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
Matikainen N; Björnson E; Söderlund S; Borén C; Eliasson B; Pietiläinen KH; Bogl LH; Hakkarainen A; Lundbom N; Rivellese A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
PLoS One; 2016; 11(1):e0145890. PubMed ID: 26752550
[TBL] [Abstract][Full Text] [Related]
15. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
Aoki K; Nakamura A; Ito S; Nezu U; Iwasaki T; Takahashi M; Kimura M; Terauchi Y
Diabetes Res Clin Pract; 2007 Oct; 78(1):30-3. PubMed ID: 17493703
[TBL] [Abstract][Full Text] [Related]
16. Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men.
Aoki K; Kamiyama H; Masuda K; Togashi Y; Terauchi Y
Endocr J; 2013; 60(4):493-9. PubMed ID: 23257734
[TBL] [Abstract][Full Text] [Related]
17. Effects of consumption of main and side dishes with white rice on postprandial glucose, insulin, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 responses in healthy Japanese men.
Kameyama N; Maruyama C; Matsui S; Araki R; Yamada Y; Maruyama T
Br J Nutr; 2014 May; 111(9):1632-40. PubMed ID: 24507870
[TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
19. Gut carbohydrate inhibits GIP secretion via a microbiota/SCFA/FFAR3 pathway.
Lee EY; Zhang X; Miyamoto J; Kimura I; Taknaka T; Furusawa K; Jomori T; Fujimoto K; Uematsu S; Miki T
J Endocrinol; 2018 Dec; 239(3):267-276. PubMed ID: 30400014
[TBL] [Abstract][Full Text] [Related]
20. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
